Trump administration pushes the FDA to formalize its release of drug rejection letters via new rulemaking, with DTC ad and Phase 1 rules also on the agenda.
July 8, 2026 12:04 PM EDT
PharmaFDA+
HHS lays groundwork for new FDA rule on releasing the CRLs
Zachary Brennan
The Trump administration is pushing the FDA to cement the details behind its proactive public release of rejection letters sent to pharma companies.
The FDA has paused a controversial policy of releasing letters describing its rationale for rejecting drugs, Fierce Biotech has…
HHS launches clinical trial reforms — including new pilot programs and updated FDA guidance — to accelerate US drug development…
The FDA is going forward with an investigation into the safet | The FDA is going forward with an investigation into the safety of…
Federal health officials aim to speed up drug development and better compete with China.
With questions already swirling about the actual affordability impact of t | With questions already swirling about the actual…
The FDA's pace of approvals has held up despite staff cuts, with 23 novel drugs cleared by June — the most since 2023.
